FDA denies giving green signal to Actavis hypertension treatment

December 24, 2014 8:47 PM

7 0

The US health regulator Food and Drug Administration (FDA) has denied approval to generic drug maker Actavis Plc for its hypertension treatment comprising a fixed-dose combination of valsartan and nebivolol.

Responding over the FDA’s decision, the company in a released statement said that it would first review the complete response letter of the regulating authority and then take decision on its further steps.

Read more

To category page